Savara (SVRA) Lifted to “Hold” at BidaskClub

BidaskClub upgraded shares of Savara (NASDAQ:SVRA) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.

Other analysts have also recently issued research reports about the company. ValuEngine cut Savara from a hold rating to a sell rating in a report on Wednesday, November 21st. Zacks Investment Research cut Savara from a hold rating to a sell rating in a report on Friday, March 8th. Finally, HC Wainwright reiterated a buy rating and set a $22.00 target price on shares of Savara in a report on Thursday, December 20th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $24.75.

Shares of NASDAQ:SVRA opened at $8.13 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 10.23 and a quick ratio of 10.23. Savara has a 1 year low of $6.21 and a 1 year high of $14.06. The stock has a market cap of $298.24 million, a PE ratio of -4.62 and a beta of 0.86.

In related news, CEO Robert N. Neville purchased 23,517 shares of the firm’s stock in a transaction on Friday, December 21st. The stock was purchased at an average price of $6.38 per share, for a total transaction of $150,038.46. Following the acquisition, the chief executive officer now directly owns 498,028 shares in the company, valued at $3,177,418.64. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.10% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Savara by 1.4% in the 4th quarter. BlackRock Inc. now owns 2,199,980 shares of the company’s stock worth $16,654,000 after acquiring an additional 29,686 shares during the period. Vanguard Group Inc. boosted its holdings in Savara by 23.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,246,240 shares of the company’s stock worth $13,908,000 after acquiring an additional 238,358 shares during the period. Vanguard Group Inc boosted its holdings in Savara by 23.6% in the 3rd quarter. Vanguard Group Inc now owns 1,246,240 shares of the company’s stock worth $13,908,000 after acquiring an additional 238,358 shares during the period. Sectoral Asset Management Inc boosted its holdings in Savara by 5.0% in the 4th quarter. Sectoral Asset Management Inc now owns 846,500 shares of the company’s stock worth $6,408,000 after acquiring an additional 40,000 shares during the period. Finally, Sofinnova Investments Inc. boosted its holdings in Savara by 8.0% in the 4th quarter. Sofinnova Investments Inc. now owns 754,372 shares of the company’s stock worth $5,711,000 after acquiring an additional 56,147 shares during the period. Hedge funds and other institutional investors own 48.71% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Recommended Story: Trading Strategy Examples and Plans

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.